Paramètres des cookies

Ce site web utilise des cookies à des fins d'optimisation et d'analyse statistique et pour afficher des annonces personnalisées. Pour plus d'informations, veuillez svp. consulter notre déclaration de confidentialité sur la protection de données personnelles.

Sartorius AG

euro adhoc: Sartorius AG
Nine-month earnings for 2004 already above full-year earnings for 2003
Group sales revenue and order intake significantly up from the previous year’s level
Debt further reduced
Full-year targets unchanged

28.10.2004 – 08:36

Disclosure announcement transmitted by euro adhoc.
  The issuer is responsible for the content of this announcement.
In the first nine-month period of 2004, the Sartorius Group increased
its sales revenue by 3.9% (currency-adjusted: 6.6%) to €337.5 million
from €324.8 million a year ago. We raised sales revenue of the
Biotechnology Division by 2.9% (currency-adjusted:  5.7%) to €170.8
million (previous year:  €166.1 million), and that of the
Mechatronics Division by 5.0% (currency-adjusted: 7.4%) to €166.6
million (previous year: €158.7 million).
Concerning order intake, we posted a substantial increase of 9.1%
(currency-adjusted: 12.3%) to €347.6 million (previous year:  €318.6
million). For the Biotechnology Division, order intake rose 10.1%
(currency-adjusted: 13.8%); for the Mechatronics Division, order
intake climbed 8.1% (currency-adjusted: 10.7%).
We boosted EBITDA in the first nine-month period of 2004 to €36.6
million from €16.6 million a year ago and improved EBIT to €20.3
million (previous year:  - €0.7 million). We raised EBIT for the
Biotechnology Division to €10.2 million (previous year:  €0.7
million); and increased that for the Mechatronics Division to €10.1
million (previous year: - €1.5 million).
We primarily used net cash flow of €21.8 million (previous year: 
€26.6 million) to reduce our net debt to €92.1 million (reporting
date on December 31, 2003: €105.0 million).
We continue to adhere to our full-year targets for increasing sales
revenue in the mid- to upper percentage range of one digit and for
doubling EBIT.
end of announcement                    euro adhoc 28.10.2004 08:00:00 

Further inquiry note:

Heiko Imöhl
Vice President
Treasury & Investor Relations
phone : +49 551 308 4034

Branche: Biotechnology
ISIN: DE0007165607
WKN: 716560
Index: Prime Standard, CDAX, Prime All Share, Technologie All Share
Börsen: Berliner Wertpapierbörse / free trade
Hamburger Wertpapierbörse / free trade
Baden-Württembergische Wertpapierbörse / free trade
Börse Düsseldorf / free trade
Bayerische Börse / free trade
Bremer Wertpapierbörse (BWB) / free trade
Frankfurter Wertpapierbörse / official dealing
Niedersächsische Börse zu Hannover / official dealing

Plus de actualités: Sartorius AG
Plus de actualités: Sartorius AG